Get the Stockscreener App
25.87
4.15%
1.03
Urogen Pharma Ltd stock is traded at $25.87, with a volume of 772.67K.
It is up +4.15% in the last 24 hours and up +42.61% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$24.84
Open:
$24.72
24h Volume:
772.67K
Relative Volume:
0.64
Market Cap:
$1.21B
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-7.049
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+8.88%
1M Performance:
+42.61%
6M Performance:
+520.38%
1Y Performance:
+123.98%
1-Day Range:
$24.69
$26.09
1-Week Range:
$22.70
$26.28
52-Week Range:
$3.42
$26.28
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
25.87 | 1.16B | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Will UroGen Pharma Ltd. stock attract more institutional investors2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
UroGen Pharma CMO Schoenberg sells $250,000 in shares By Investing.com - Investing.com South Africa
UroGen Pharma CMO Schoenberg sells $250,000 in shares - Investing.com
Does UroGen Pharma Ltd. stock trade at a discount to peersQuarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
Will UroGen Pharma Ltd. (UR8) stock sustain dividend payoutsOptions Play & Precise Trade Entry Recommendations - newser.com
Is UroGen Pharma Ltd. (UR8) stock prepared for digital transitionEarnings Miss & Real-Time Volume Triggers - newser.com
Is UroGen Pharma Ltd. (UR8) stock undervalued after correction2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
Urogen Pharma Ltd stock hits 52-week high at 25.2 USD - Investing.com Nigeria
Will UroGen Pharma Ltd. (UR8) stock gain from green policiesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Why global investors buy UroGen Pharma Ltd. (UR8) stockWeekly Market Summary & Safe Capital Allocation Plans - newser.com
Is UroGen Pharma Ltd. (UR8) stock good for long term investing2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Why UroGen Pharma Ltd. (UR8) stock stays on buy listsShort Setup & Safe Entry Momentum Stock Tips - newser.com
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs - MSN
Why UroGen Pharma Ltd. stock could be next big winner2025 Risk Factors & Smart Money Movement Alerts - newser.com
UroGen Pharma Ltd Stock Analysis and ForecastCapital Gains Strategies & Free High Yield Portfolio Picks - earlytimes.in
Is UroGen Pharma Ltd. stock bottoming outDividend Hike & Expert Approved Momentum Trade Ideas - newser.com
UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN) - simplywall.st
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):